October 28, 2022

BioPharma Dive looks at the market downturn effect on industry startups

Suzanne Struglinski
Public relations manager
by
Suzanne Struglinski

Biotech startups have not had an easy time in 2022. After record numbers of new biotech stock offerings in 2020 and 2021, a market downturn shut the door on IPOs for many young drugmakers, forcing their venture capital backers to adjust. While markets have steadied so far through the second half of 2022, the effects are still lingering as would-be investors keep their pencils sharpened.

BioPharma Dive Reporter Gwendolyn Wu will discuss what happens now with four industry leaders in the "Building a biotech in a turbulent market" virtual event on Tuesday.

From 2-3 p.m. EDT on Nov. 1,  Wu’s guests are:

  • Christiana Bardon, M.D., M.B.A.
    Co-Managing Partner
    BioImpact Capital, an affiliate of MPM Capital
  • Mira Chaurushiya, PhD
    Senior Partner
    Westlake Village BioPartners
  • Chris Garabedian
    Chairman and CEO
    Xontogeny
  • Benjamin L. Oakes, PhD
    Co-founder, President, and CEO
    Scribe Therapeutics

To complete the free registration for this event or subscribe to BioPharma Dive, visit the event website. A recording of the event will be available for viewing.

For media inquiries about this event, or to speak with these reporters, email media@industrydive.com.

{{end}}

Industry Dive is a leading business journalism company. Nearly 13 million decision-makers across 20+ competitive industries rely on our exclusive insight and analysis delivered through 28 publications.

‍

‍

Topic
###